US Patent Issued to Impact Therapeutics (Shanghai) on June 16 for "Substituted imidazoquinoxaline compounds and uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,653,830, issued on June 16, was assigned to Impact Therapeutics (Shanghai) Inc (Shanghai).

"Substituted imidazoquinoxaline compounds and uses thereof" was invented by Sui Xiong Cai (Shanghai), Ye Edward Tian (Shanghai) and Xiaozhu Wang (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides substituted imidazo[1,5-a]quinoxaline and related compounds as kinase inhibitors, and their uses. Specifically, the disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof or prodrugs thereof, wherein, A1-A3, Cy and R1-R2 are defined herein. The compounds of Formula I are kinase inhibitors. Therefore, th...